Valuation: PYC Therapeutics Limited

Market Cap 2.47B 0 1.71B 1.52B 1.42B 1.29B 2.44B 165B 17.17B 6.65B 83.79B 6.42B 6.28B 269B P/E 2027 *
-32.6x
P/E 2028 * -29.2x
Enterprise Value 1.99B 0 1.38B 1.22B 1.14B 1.04B 1.96B 133B 13.83B 5.35B 67.5B 5.17B 5.06B 217B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
66.17%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: PYC Therapeutics Limited

Manager TitleAgeSince
Chief Executive Officer 42 19/08/2020
Director of Finance/CFO 47 07/07/2026
Chief Tech/Sci/R&D Officer - 01/08/2025
Director TitleAgeSince
Director/Board Member 42 30/11/2018
Director/Board Member - 22/09/2025
Chairman 66 18/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.71B
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.07%-1.47%+24.52%+78.33% 59.26B
+0.86%-1.30%+3.58%+33.60% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.50%-0.52%+52.76%+153.99% 43.6B
Weighted average by Cap. -0.01%-0.32%+57.94%+145.67%

Financials

2027 *2028 *
Net sales - -
Net income -78.66M -0 -54.45M -48.36M -45.23M -41.22M -77.59M -5.24B -547M -212M -2.67B -204M -200M -8.58B -86.4M -0 -59.81M -53.12M -49.68M -45.27M -85.23M -5.76B -601M -233M -2.93B -225M -220M -9.42B
Net Debt -480M -0 -332M -295M -276M -252M -474M -32B -3.34B -1.29B -16.3B -1.25B -1.22B -52.34B -456M -0 -315M -280M -262M -239M -449M -30.37B -3.17B -1.23B -15.46B -1.18B -1.16B -49.67B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-